Publication date: Jun 12, 2019
The FDA has started its two-day advisory committee meeting to determine if higher doses of opioids should be limited or removed from the market.
During the meeting, the FDA is soliciting feedback from clinical, patient, public health and research communities to better understand current clinical use of higher-dose opioids, situations that may warrant the use of higher doses and frequency of harm associated with higher doses.
- CHIME Opioid Task Force Playbook
- Senate committee focuses on pain sufferers denied painkillers amid opioid crisis
- Best Pain Management Practices Outlined in New HHS Report
- Can Cutting Off Opioids Too Quickly Harm Patients? Feds Say Yes.